ArticleAcute and critical care2026
Peripheral administration of 11.7% hypertonic saline and phlebitis risk in acute ischemic stroke requiring hyperosmolar therapy in South Korea.
Article in Acute and critical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHypertonic saline (HTS) is used for hyperosmolar therapy in acute ischemic stroke (AIS) but is traditionally administered via central venous catheter to minimize vascular complications. Procedural burden and urgency often necessitate peripheral administration in practice. We investigated phlebitis risk associated with peripheral 11.7% HTS in AIS patients requiring hyperosmolar therapy.
methodsThis retrospective study included 200 AIS patients receiving hyperosmolar therapy with mannitol (January 2022-December 2024), classified into an HTS group (n=67) receiving additional peripheral 11.7% NaCl and a no-HTS group (n=133). Phlebitis was assessed using the Infusion Nurses Society Phlebitis Scale. The primary outcome was phlebitis within 72 hours of therapy initiation. Multivariable logistic regression assessed the independent association between HTS use and phlebitis, with a secondary analysis examining frequency-dependent risk.
resultsPhlebitis occurred in 31.3% (21/67) of the HTS group versus 15.8% (21/133) of the noHTS group (P=0.016). Among those with phlebitis, most cases were mild (grade 1, 90.5%; grade 2, 9.5%), with no grade 3 or higher events. HTS was independently associated with phlebitis (adjusted OR, 2.19; 95% CI, 1.02-4.70; P=0.044) but not with mortality or hospital length of stay. Single administration was not associated with increased risk, whereas two administrations (adjusted OR, 5.43; P=0.005) and three or more (adjusted OR, 3.59; P=0.016) were associated with markedly elevated risk (P for trend=0.002).
conclusionsPeripheral 11.7% HTS was associated with increased phlebitis risk, though cases were predominantly mild. Risk increased with repeated rather than single-dose administration, suggesting caution is warranted when multiple peripheral doses are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.